GALECTIN THERAPEUTICS INC. Earnings Per Share (Basic)
GALECTIN THERAPEUTICS INC. (GALT) reported Earnings Per Share (Basic) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.14.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.08.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.09.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.13.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for fiscal 2025 was -$0.48.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for fiscal 2024 was -$0.76.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for fiscal 2023 was -$0.74.
- GALECTIN THERAPEUTICS INC. earnings per share, basic for fiscal 2022 was -$0.65.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.14 10-Q · filed 2026-08-14 | -$0.22 10-Q · filed 2026-08-14 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2026-03-31 | -$0.08 10-Q · filed 2026-05-15 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.48 10-K · filed 2026-03-31 |
| 2025-09-30 | -$0.13 10-Q · filed 2025-11-14 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.40 10-Q · filed 2025-11-14 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-06-30 | -$0.12 10-Q · filed 2026-08-14 | -$0.27 10-Q · filed 2026-08-14 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-03-31 | -$0.15 10-Q · filed 2026-05-15 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-05-15 |
| 2024-12-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.76 10-K · filed 2026-03-31 |
| 2024-09-30 | -$0.18 10-Q · filed 2025-11-14 | -$0.38 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$0.57 10-Q · filed 2025-11-14 | -$0.73 derived: net income ÷ weighted average shares · filed 2025-11-14 |
| 2024-06-30 | -$0.20 10-Q · filed 2025-08-14 | -$0.39 10-Q · filed 2025-08-14 | -$0.55 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$0.78 derived: net income ÷ weighted average shares · filed 2025-08-14 |
| 2024-03-31 | -$0.19 10-Q · filed 2025-05-15 | -$0.35 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$0.58 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$0.74 derived: net income ÷ weighted average shares · filed 2025-05-15 |
| 2023-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.55 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.74 10-K · filed 2025-03-31 |
| 2023-09-30 | -$0.24 10-Q · filed 2024-11-14 | -$0.39 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.58 10-Q · filed 2024-11-14 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-06-30 | -$0.15 10-Q · filed 2024-08-13 | -$0.35 10-Q · filed 2024-08-13 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-08-13 |
| 2023-03-31 | -$0.19 10-Q · filed 2024-05-15 | -$0.37 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$0.52 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$0.68 derived: net income ÷ weighted average shares · filed 2024-05-15 |
| 2022-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$0.32 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$0.49 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$0.65 10-K · filed 2024-03-29 |
| 2022-09-30 | -$0.14 10-Q · filed 2023-11-13 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.47 10-Q · filed 2023-11-13 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2022-06-30 | -$0.16 10-Q · filed 2023-08-14 | -$0.33 10-Q · filed 2023-08-14 | -$0.45 derived: net income ÷ weighted average shares · filed 2023-08-14 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-08-14 |
| 2022-03-31 | -$0.17 10-Q · filed 2023-05-15 | -$0.29 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.43 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.58 derived: net income ÷ weighted average shares · filed 2023-05-15 |
| 2021-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.27 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.41 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.52 10-K · filed 2023-03-30 |
| 2021-09-30 | -$0.14 10-Q · filed 2022-11-14 | -$0.29 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.40 10-Q · filed 2022-11-14 | -$0.54 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$0.15 10-Q · filed 2022-08-15 | -$0.26 10-Q · filed 2022-08-15 | -$0.40 derived: net income ÷ weighted average shares · filed 2022-08-15 | -$0.50 derived: net income ÷ weighted average shares · filed 2022-08-15 |
| 2021-03-31 | -$0.11 10-Q · filed 2022-05-16 | -$0.25 derived: net income ÷ weighted average shares · filed 2022-05-16 | -$0.35 derived: net income ÷ weighted average shares · filed 2022-05-16 | |
| 2020-12-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.41 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$0.10 10-Q · filed 2021-11-15 | -$0.28 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |